Ireland
--:--IST
Priya Life Science Sponsor trial record
Sponsor · clinical trials

Borstkanker Onderzoek Groep clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our Netherlands register with Borstkanker Onderzoek Groep as lead sponsor. Synced 12 Nov 2026
4Current trials
0Recruiting now
7Drugs in these trials
1Trial register
At a glance

Borstkanker Onderzoek Groep is the lead sponsor of 4 current clinical trials in our Netherlands register. None of its ClinicalTrials.gov trials is recruiting at the moment. The most common phase is Phase 2. The drugs named most often in its trials are Fulvestrant, Letrozole and Ribociclib. The most-studied condition is Breast Cancer.

ClinicalTrials.gov trials by status

  • Active, closed4100%

Trials by phase

  • Phase 2375%
  • Phase 3125%
01

Clinical trials sponsored by Borstkanker Onderzoek Groep

4 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
Image-guided De-escalation of Neo-adjuvant Chemotherapy in HER2-positive Breast Cancer: the TRAIN-3 Study
NCT03820063 · ClinicalTrials.gov ↗ · Breast Cancer
Phase 2 Active, closed 2019-02 Netherlands
Endocrine Therapy Plus CDK4/6 in First or Second Line for Hormone (SONIA) Receptor Positive Advanced Breast Cancer
NCT03425838 · ClinicalTrials.gov ↗ · Breast Neoplasm Female
Phase 3 Active, closed 2017-11 Netherlands
Tailoring NEOadjuvant Therapy in Hormone Receptor Positive, HER2 Negative, Luminal Breast Cancer.
NCT03283384 · ClinicalTrials.gov ↗ · Breast Neoplasms
Phase 2 Active, closed 2019-06 Netherlands
SEQUence of Endocrine Therapy in Advanced Luminal Breast Cancer (SEQUEL-Breast)
NCT05392608 · ClinicalTrials.gov ↗ · Neoplasm, Breast, Congenital, Familial and Genetic Disorders
Phase 2 Active, closed 2022-06 Netherlands

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in Borstkanker Onderzoek Groep trials

7 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in Borstkanker Onderzoek Groep trials

5 conditions
Breast Cancer1Breast Neoplasm Female1Breast Neoplasms1Neoplasm, Breast1Congenital, Familial and Genetic Disorders1
04

By trial register

RegisterTrialsRecruiting
Clinical trials in Netherlands40

A trial with sites in more than one country appears in each of those registers.

05

Other sponsors in Breast Cancer

SponsorTrials
Fudan University50
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University21
AstraZeneca18
Second Affiliated Hospital, Zhejiang University, School of Medicine18
University Health Network, Toronto16
Institut du Cancer de Montpellier - Val d'Aurelle16
Sunnybrook Health Sciences Centre15
Shengjing Hospital15
European Institute of Oncology14
Pfizer12

Sponsors with the most current trials registered for this condition.

06

Questions about Borstkanker Onderzoek Groep trials

How many clinical trials does Borstkanker Onderzoek Groep sponsor?

Borstkanker Onderzoek Groep is the lead sponsor of 4 current trials on ClinicalTrials.gov in our Netherlands register, as of the registry sync on 12 November 2026. Completed and withdrawn studies are not counted.

Are Borstkanker Onderzoek Groep trials recruiting?

Not at the moment. None of its 4 ClinicalTrials.gov trials is recruiting; they are active but closed to enrolment, not yet open, or enrolling by invitation. Only the study team can confirm whether a patient is eligible.

Which drugs is Borstkanker Onderzoek Groep testing?

Its current trials name 7 drugs and biologicals as interventions. The most frequent are Fulvestrant (2), Letrozole (2), Ribociclib (2), Abemaciclib (1) and Alpelisib (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 12 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.